168 related articles for article (PubMed ID: 24388920)
1. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia.
Garcia FA; Cornelison T; Nuño T; Greenspan DL; Byron JW; Hsu CH; Alberts DS; Chow HH
Gynecol Oncol; 2014 Feb; 132(2):377-82. PubMed ID: 24388920
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
[TBL] [Abstract][Full Text] [Related]
3. Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial.
Stockfleth E; Beti H; Orasan R; Grigorian F; Mescheder A; Tawfik H; Thielert C
Br J Dermatol; 2008 Jun; 158(6):1329-38. PubMed ID: 18363746
[TBL] [Abstract][Full Text] [Related]
4. Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.
Chow HH; Hakim IA; Vining DR; Crowell JA; Ranger-Moore J; Chew WM; Celaya CA; Rodney SR; Hara Y; Alberts DS
Clin Cancer Res; 2005 Jun; 11(12):4627-33. PubMed ID: 15958649
[TBL] [Abstract][Full Text] [Related]
5. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
7. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
[TBL] [Abstract][Full Text] [Related]
8. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
[TBL] [Abstract][Full Text] [Related]
9. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment.
Hildesheim A; Gonzalez P; Kreimer AR; Wacholder S; Schussler J; Rodriguez AC; Porras C; Schiffman M; Sidawy M; Schiller JT; Lowy DR; Herrero R;
Am J Obstet Gynecol; 2016 Aug; 215(2):212.e1-212.e15. PubMed ID: 26892991
[TBL] [Abstract][Full Text] [Related]
10. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.
Zhu FC; Chen W; Hu YM; Hong Y; Li J; Zhang X; Zhang YJ; Pan QJ; Zhao FH; Yu JX; Zhang YS; Yang X; Zhang CF; Tang H; Zhang H; Lebacq M; David MP; Datta SK; Struyf F; Bi D; Descamps D;
Int J Cancer; 2014 Dec; 135(11):2612-22. PubMed ID: 24740596
[TBL] [Abstract][Full Text] [Related]
12. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.
Harper DM; Nieminen P; Donders G; Einstein MH; Garcia F; Huh WK; Stoler MH; Glavini K; Attley G; Limacher JM; Bastien B; Calleja E
Gynecol Oncol; 2019 Jun; 153(3):521-529. PubMed ID: 30955915
[TBL] [Abstract][Full Text] [Related]
14. Protective effects of green tea extracts (polyphenon E and EGCG) on human cervical lesions.
Ahn WS; Yoo J; Huh SW; Kim CK; Lee JM; Namkoong SE; Bae SM; Lee IP
Eur J Cancer Prev; 2003 Oct; 12(5):383-90. PubMed ID: 14512803
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities.
Nguyen MM; Ahmann FR; Nagle RB; Hsu CH; Tangrea JA; Parnes HL; Sokoloff MH; Gretzer MB; Chow HH
Cancer Prev Res (Phila); 2012 Feb; 5(2):290-8. PubMed ID: 22044694
[TBL] [Abstract][Full Text] [Related]
16. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.
FUTURE II Study Group
N Engl J Med; 2007 May; 356(19):1915-27. PubMed ID: 17494925
[TBL] [Abstract][Full Text] [Related]
17. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Trimble CL; Morrow MP; Kraynyak KA; Shen X; Dallas M; Yan J; Edwards L; Parker RL; Denny L; Giffear M; Brown AS; Marcozzi-Pierce K; Shah D; Slager AM; Sylvester AJ; Khan A; Broderick KE; Juba RJ; Herring TA; Boyer J; Lee J; Sardesai NY; Weiner DB; Bagarazzi ML
Lancet; 2015 Nov; 386(10008):2078-2088. PubMed ID: 26386540
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
Xiao M; Xu Q; Li H; Gao H; Bie Y; Zhang Z
Medicine (Baltimore); 2016 Jan; 95(3):e2555. PubMed ID: 26817906
[TBL] [Abstract][Full Text] [Related]
19. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L; Hopkins L; Hutton B; Fergusson D
CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of human papillomavirus infection between biopsy and excision of cervical intraepithelial neoplasia: results from the ZYC101a protocol.
Crum CP; Beach KJ; Hedley ML; Yuan L; Lee KR; Wright TC; Urban RG
J Infect Dis; 2004 Apr; 189(8):1348-54. PubMed ID: 15073670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
